%0 Journal Article %T Azithromycin in Pityriasis Rosea: A Double-Blind, Placebo-Controlled Clinical Trial %J Iranian Journal of Dermatology %I Iranian Society of Dermatology %Z 2717-0721 %A Amir Hooshang, Ehsani %A Siavash, Toosi %A Pedram, Noormohamadpour %A Mahboubeh, Hosseini %A Leila, Nazeman %D 2008 %\ 12/01/2008 %V 11 %N 4 %P 143-146 %! Azithromycin in Pityriasis Rosea: A Double-Blind, Placebo-Controlled Clinical Trial %K azithromycin %K pityriasis rosea %K treatment %R %X Background: Pityriasis rosea is an inflammatory skin disorder with a known response to erythromycin. Considering similarities between erythromycin and azithromycin and lesser adverse effects of the latter, in a pilot study, we gave azithromycin to seven patients with pityriasis rosea and observed a noticeable improvement. The aim of this study was to evaluate the efficacy of azithromycin in patients with pityriasis rosea.Methods: A double-blind, placebo-controlled clinical trial was performed in our clinic. Sixty patients over a period of 20 months were alternatively assigned to the treatment group or the placebo group. Patients in the treatment group received azithromycin, 250 mg/day, for 14 days. The response was categorized as complete response, partial response, or no response. All patients were followed up for 2 months.Results: Age at presentation, sex, and average duration of the disease were comparable in both groups. Complete response was observed in 19 patients (63.3 %) in the treatment group and two in the placebo group (p<0.0001).Conclusion: Oral azithromycin is effective in treating patients with pityriasis rosea. %U https://www.iranjd.ir/article_98068_4582cff86cb4501a047581682ddd9de9.pdf